While reduced ApoE gene dosage consistently ameliorates AD phenotypes [30, 33], there has been conflicting reports on gene dosage effects of TREM2 in AβPP transgenic mice [7, 77, 78]. This evidence concerns the gene APOE and Alzheimer disease.